JP2015536999A5 - - Google Patents

Download PDF

Info

Publication number
JP2015536999A5
JP2015536999A5 JP2015542030A JP2015542030A JP2015536999A5 JP 2015536999 A5 JP2015536999 A5 JP 2015536999A5 JP 2015542030 A JP2015542030 A JP 2015542030A JP 2015542030 A JP2015542030 A JP 2015542030A JP 2015536999 A5 JP2015536999 A5 JP 2015536999A5
Authority
JP
Japan
Prior art keywords
molindone
receptor
pharmaceutical formulation
formulation according
human subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015542030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536999A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/069863 external-priority patent/WO2014078394A1/en
Publication of JP2015536999A publication Critical patent/JP2015536999A/ja
Publication of JP2015536999A5 publication Critical patent/JP2015536999A5/ja
Pending legal-status Critical Current

Links

JP2015542030A 2012-11-13 2013-11-13 攻撃性の治療法 Pending JP2015536999A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261725883P 2012-11-13 2012-11-13
US61/725,883 2012-11-13
US201261727570P 2012-11-16 2012-11-16
US61/727,570 2012-11-16
PCT/US2013/069863 WO2014078394A1 (en) 2012-11-13 2013-11-13 Method of treatment of aggression

Publications (2)

Publication Number Publication Date
JP2015536999A JP2015536999A (ja) 2015-12-24
JP2015536999A5 true JP2015536999A5 (enExample) 2016-08-04

Family

ID=49681174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542030A Pending JP2015536999A (ja) 2012-11-13 2013-11-13 攻撃性の治療法

Country Status (7)

Country Link
US (1) US20140135326A1 (enExample)
EP (2) EP2919787A1 (enExample)
JP (1) JP2015536999A (enExample)
AU (2) AU2013344920A1 (enExample)
CA (1) CA2888725A1 (enExample)
MX (1) MX2015005937A (enExample)
WO (1) WO2014078394A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
EP3449402A1 (en) * 2016-04-29 2019-03-06 Supernus Pharmaceuticals, Inc. Methods, system, and kit for monitoring, diagnosing, and treating impulsive aggression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
CA3014688A1 (en) * 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
US8748472B2 (en) * 2010-03-31 2014-06-10 Supernus Pharmaceuticals, Inc. Stabilized formulations of CNS compounds

Similar Documents

Publication Publication Date Title
JP2014507482A5 (enExample)
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
TN2015000278A1 (en) Autotaxin inhibitors
WO2014127917A8 (en) Combination of vaccination and inhibition of the pd-1 pathway
IL224048B (en) Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease
JP2012126725A5 (enExample)
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
IL235923A0 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
LT4104824T (lt) Kompozicijos, skirtos panaudoti taikant pacientams su didele širdies ir kraujagyslių ligos rizika antsvorio ir nutukimo gydymo būdą
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12012502082A1 (en) Combination of active loaded granules with additional actives
JP2016530291A5 (enExample)
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
JP2015536999A5 (enExample)
EP2978421A4 (en) STABLE NANO COMPOSITION WITH DOCETAXEL, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
JP2016175884A5 (enExample)
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
ZA201500410B (en) Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201590732A1 (ru) Диспергируемая таблетка